YHB Investment Advisors Inc. Has $765,000 Stock Holdings in Abbott Laboratories (NYSE:ABT)

YHB Investment Advisors Inc. boosted its position in shares of Abbott Laboratories (NYSE:ABTGet Rating) by 2.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,038 shares of the healthcare product maker’s stock after buying an additional 200 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Abbott Laboratories were worth $765,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ABT. Bourgeon Capital Management LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $30,000. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $30,000. Dravo Bay LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $32,000. Delos Wealth Advisors LLC lifted its stake in shares of Abbott Laboratories by 100.9% in the 4th quarter. Delos Wealth Advisors LLC now owns 231 shares of the healthcare product maker’s stock valued at $33,000 after purchasing an additional 116 shares during the period. Finally, Holloway Wealth Management LLC lifted its stake in shares of Abbott Laboratories by 175.0% in the 1st quarter. Holloway Wealth Management LLC now owns 275 shares of the healthcare product maker’s stock valued at $33,000 after purchasing an additional 175 shares during the period. Institutional investors and hedge funds own 73.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on ABT shares. Morgan Stanley lowered their price objective on shares of Abbott Laboratories from $134.00 to $132.00 and set an “overweight” rating for the company in a research report on Thursday, July 21st. Cowen lowered their target price on Abbott Laboratories from $150.00 to $130.00 in a report on Wednesday, July 13th. Citigroup lowered their target price on Abbott Laboratories from $125.00 to $123.00 and set a “buy” rating for the company in a report on Thursday, July 21st. BTIG Research decreased their price objective on Abbott Laboratories from $130.00 to $126.00 and set a “buy” rating for the company in a report on Monday, July 18th. Finally, Evercore ISI decreased their price objective on Abbott Laboratories to $112.00 in a report on Friday, July 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.46.

Abbott Laboratories Trading Up 0.4 %

Shares of ABT stock opened at $101.07 on Friday. The firm has a 50 day moving average price of $107.10 and a two-hundred day moving average price of $111.67. The company has a quick ratio of 1.54, a current ratio of 2.01 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $177.00 billion, a PE ratio of 21.10, a price-to-earnings-growth ratio of 3.79 and a beta of 0.72. Abbott Laboratories has a 12-month low of $99.85 and a 12-month high of $142.60.

Abbott Laboratories (NYSE:ABTGet Rating) last issued its quarterly earnings data on Wednesday, July 20th. The healthcare product maker reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.34. The firm had revenue of $11.26 billion during the quarter, compared to the consensus estimate of $10.37 billion. Abbott Laboratories had a net margin of 18.78% and a return on equity of 29.38%. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the business posted $1.17 earnings per share. As a group, analysts predict that Abbott Laboratories will post 4.99 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Shareholders of record on Friday, October 14th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, October 13th. This represents a $1.88 annualized dividend and a yield of 1.86%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 39.25%.

Insiders Place Their Bets

In other news, SVP Fernando Mateus sold 2,457 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $109.05, for a total value of $267,935.85. Following the completion of the sale, the senior vice president now directly owns 14,503 shares in the company, valued at $1,581,552.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Daniel J. Starks sold 50,000 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $109.14, for a total value of $5,457,000.00. Following the completion of the sale, the director now directly owns 6,923,500 shares in the company, valued at $755,630,790. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Fernando Mateus sold 2,457 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $109.05, for a total transaction of $267,935.85. Following the completion of the transaction, the senior vice president now directly owns 14,503 shares in the company, valued at $1,581,552.15. The disclosure for this sale can be found here. Insiders sold 204,788 shares of company stock worth $21,776,756 over the last three months. Insiders own 0.52% of the company’s stock.

About Abbott Laboratories

(Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Further Reading

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.